HEALTHX NSE filing

Health X Platform Limited Reports Q2 FY27 Unaudited Financial Results

The RealCase readMedium impact Negative

Health X Platform Limited reported Q2 FY27 unaudited results. Standalone net loss for Q2 FY27 was ₹31.85 lakhs (vs. ₹51.43 lakhs loss YoY). Consolidated net loss for Q2 FY27 was ₹1,185.59 lakhs (vs. ₹197.48 lakhs profit YoY). The company is awaiting approvals for a Composite Scheme of Arrangement and Amalgamation.

Why it matters

The results show a substantial increase in consolidated losses, which could impact investor sentiment. However, the ongoing amalgamation scheme and the company's core business performance will also influence the overall impact.

The market read

The company reported a significant increase in net loss on a consolidated basis for the quarter and half-year ended September 30, 2026, compared to the previous year, indicating a negative financial performance trend.

Health X Platform Limited (formerly Sastasundar Ventures Limited) announced the outcome of its Board Meeting held on November 14, 2026. The Board approved and took on record the Unaudited Financial Results for the quarter and half year ended September 30, 2026, for both standalone and consolidated entities.

The financial results were reviewed by the Audit Committee and the Statutory Auditor provided a Limited Review Report. The Board meeting commenced at 12:30 PM IST and concluded at 2:00 PM IST.

The company's standalone results for the quarter ended September 30, 2026, showed a net loss of ₹31.85 lakhs, compared to a net loss of ₹51.43 lakhs in the same period last year. For the half-year ended September 30, 2026, the standalone net loss was ₹83.28 lakhs, an improvement from ₹38.99 lakhs in the prior year period.

Consolidated results for the quarter ended September 30, 2026, reported a net loss of ₹1,185.59 lakhs, a significant change from a net profit of ₹197.48 lakhs in the corresponding quarter of the previous year. The consolidated net loss for the half-year ended September 30, 2026, stood at ₹1,326.37 lakhs, compared to a net profit of ₹1,154.94 lakhs in the same period last year.

The company also disclosed that the Board, on June 10, 2026, approved a Composite Scheme of Arrangement and Amalgamation involving Health X Platform Limited, Microsec Resources Private Limited, Innogrow Technologies Limited, and Sastasundar Healthbuddy Limited, effective from April 1, 2026. However, no accounting effect has been given for this scheme in the current financial results pending necessary approvals. Expenses of ₹14.75 lakhs were incurred in connection with this scheme during the previous quarter.

Filing to action

What to do with a filing like this

Health X Platform Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Health X Platform Limited. Read the original for the full detail.

View original filing